HTD2: A Potential Drug Target for Heart Disease (G109703458)

Target Name: HTD2

NCBI ID: G109703458

HTD2

HTD2: A Potential Drug Target for Heart Disease

HTD2, or Hydroxyacyl-Thioester Dehydratase Type 2, is an enzyme that plays a crucial role in the metabolism of a type of cholesterol called low-density lipoprotein (LDL). LDL is a major risk factor for the development of heart disease and stroke, and scientists and doctors have been trying to find new ways to treat it for many years. HTD2 is a potential drug target or biomarker that may be used to diagnose and treat LDL-related diseases.

The HTD2 enzyme is a key player in the metabolism of LDL cholesterol. It is responsible for breaking down a type of LDL cholesterol called 7-ketocholesterol. 7-ketocholesterol is a toxic form of cholesterol that can cause damage to the liver and other tissues if not properly metabolized. HTD2 helps to convert 7-ketocholesterol into a less toxic form, which is then excreted from the body.

Scientists have known for many years that HTD2 is a key enzyme in the metabolism of LDL cholesterol. However, they have also found that it is involved in the production of other types of cholesterol, including low-density lipoprotein receptor-1 (LDLR1) and high-density lipoprotein receptor-1 (HDLR1). These enzymes are involved in the uptake and storage of cholesterol in the body, and their activity may be important for maintaining the balance of different types of cholesterol.

HTD2 is also involved in the metabolism of other types of cholesterol, including bile acids and steroids. These enzymes are important for maintaining the health and function of the liver, and their activity may be involved in the development and treatment of a variety of diseases.

In addition to its role in cholesterol metabolism, HTD2 is also thought to be involved in the regulation of other processes in the body. For example, it has been shown to play a role in the development and progression of certain types of cancer, and may also be involved in the development of cardiovascular disease.

As a result of its involvement in cholesterol metabolism and other processes in the body, HTD2 has been identified as a potential drug target or biomarker for a variety of diseases. For example, scientists have been studying the effects of drugs that target HTD2 on the metabolism of LDL cholesterol, with the goal of developing new treatments for heart disease and stroke.

In addition to its potential as a drug target, HTD2 is also a promising biomarker for the diagnosis of certain diseases. For example, people with high levels of HTD2 may be at increased risk of developing heart disease, and researchers have been studying the relationship between HTD2 and the risk of heart disease in people with a family history of heart disease.

In conclusion, HTD2 is a crucial enzyme involved in the metabolism of low-density lipoprotein (LDL) cholesterol. It has been shown to play a role in the development and progression of certain types of cancer, as well as the development of cardiovascular disease. As a result, HTD2 is a potential drug target or biomarker for a variety of diseases, and further research is needed to fully understand its role in the body and its potential as a treatment.

Protein Name: Hydroxyacyl-thioester Dehydratase Type 2

Functions: Mitochondrial 3-hydroxyacyl-thioester dehydratase, which may be involved in fatty acid biosynthesis

The "HTD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HTD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets